APS vs. CZO, REUN, NEPT, ATE, SBM, KNE, RVX, IMV, IOT, and RVV
Should you be buying Aptose Biosciences stock or one of its competitors? The main competitors of Aptose Biosciences include Ceapro (CZO), Reunion Neuroscience (REUN), Neptune Wellness Solutions (NEPT), Antibe Therapeutics (ATE), Sirona Biochem (SBM), Kane Biotech (KNE), Resverlogix (RVX), IMV (IMV), Innovotech (IOT), and Revive Therapeutics (RVV). These companies are all part of the "biotechnology" industry.
Aptose Biosciences vs.
Ceapro (CVE:CZO) and Aptose Biosciences (TSE:APS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, risk, analyst recommendations, media sentiment, earnings, community ranking and dividends.
Aptose Biosciences received 153 more outperform votes than Ceapro when rated by MarketBeat users. Likewise, 72.11% of users gave Aptose Biosciences an outperform vote while only 60.82% of users gave Ceapro an outperform vote.
15.1% of Aptose Biosciences shares are owned by institutional investors. 4.0% of Ceapro shares are owned by company insiders. Comparatively, 17.1% of Aptose Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Aptose Biosciences has a net margin of 0.00% compared to Ceapro's net margin of -69.73%. Aptose Biosciences' return on equity of 1,017.48% beat Ceapro's return on equity.
Ceapro has a beta of 1.38, meaning that its share price is 38% more volatile than the S&P 500. Comparatively, Aptose Biosciences has a beta of 1.36, meaning that its share price is 36% more volatile than the S&P 500.
In the previous week, Ceapro's average media sentiment score of 0.00 equaled Aptose Biosciences'average media sentiment score.
Ceapro has higher revenue and earnings than Aptose Biosciences. Ceapro is trading at a lower price-to-earnings ratio than Aptose Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Aptose Biosciences beats Ceapro on 7 of the 12 factors compared between the two stocks.
Get Aptose Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for APS and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip ChartMedia Sentiment Over Time
This chart shows the average media sentiment of TSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Aptose Biosciences Competitors List
Related Companies and Tools
This page (TSE:APS) was last updated on 2/13/2025 by MarketBeat.com Staff